Home > Dermatology > AAD 2018 > Late-breakers > Psoriasis: Selective IL-23 blocker, analysis of VOYAGE-2, dual IL-17 inhibitor and ustekinumab

Psoriasis: Selective IL-23 blocker, analysis of VOYAGE-2, dual IL-17 inhibitor and ustekinumab

Presented By
Prof. Kenneth Gordon, Medical College of Wisconsin, USA; Prof. Kristian Reich, SCIderm Research Institute, Germany; Dr Kim Papp, Probity Medical Research, Canada; Prof. Joel Gelfand, University of Pennsylvania Perelman School of Medicine, USA
Conference
AAD 2018
Psoriasis: unprecedented activity with selective IL-23 blocker The IL-23 blocker risankizumab was superior to both placebo and ustekinumab over 52 weeks in two identical, double-blind, placebo- and ustekinumab controlled Phase 3 trials (ultiMMa-1 and ultiMMa-2) [5]. Both trials compared the IL-23 inhibitor risankizumab with placebo and ustekinumab over 52 weeks in a total of 797 patients with moderate-to-severe plaque psoriasis. Patients in the placebo arm were switched over to risankizumab after 16 weeks. The primary targets were a reduction of the Psoriasis Area and Severity Index (PASI) by 90% (PASI 90) and clear or almost clear skin, according to the static Physician´s Global Assessment (sPGA 0/1). In addition, 15 secondary targets were assessed at different time points during the 52-week study. Risankizumab met all: the difference in efficacy between the drugs were all statistically significant at 16 and 52 weeks (P<0.001). At 52 week...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on